Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model

Vaccine

Volumn 26, Issue 44, 2008, Pages 5654-5661

  Usher, Cara ^a   Tilson, Lesley ^a   Olsen, Jens ^b   Jepsen, Martin ^c   Walsh, Cathal ^a,d,e   Barry, Michael ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cost effectiveness; Decision maker; HPV vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL ARTICLE; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IRELAND; PRIORITY JOURNAL; PROBABILITY; SCHOOL CHILD; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNIZATION PROGRAMS; IRELAND; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; UTERINE CERVICAL NEOPLASMS;

EID: 52949147772     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.098     Document Type: Article

References (35)

1. Yang B.H., Bray F.I., Parkin D.M., Sellors J.W., and Zhang Z.F. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 109 3 (2004) 418-424
2. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 6 (2003) 781-789
3. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 1 (2003) 37-48
4. Bergeron C., Largeron N., McAllister R., Mathevet P., and Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 24 1 (2008) 10-19
5. Brisson M., Van de Velde N., De Wals P., and Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 (2007) 5399-5408
6. Kulasingam S., Connelly L., Conway E., Hocking J.S., Myers E., Regan D.G., et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 4 (2007) 165-175
7. Boot H.J., Wallenburg I., de Melker H.E., Mangen M.J., Gerritsen A.A., van der Maas N.A., et al. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 25 (2007) 6245-6256
8. Insinga R.P., Dasbach E.J., Elbasha E.H., Puig A., and Reynales-Shigematsu L.M. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26 (2007) 128-139
9. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'shea M.K., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 25 (2007) 6257-6270
10. Ginsberg G.M., Fisher M., Ben-Shahar I., and Bornstein J. Cost-utility analysis of vaccination against HPV in Israel. Vaccine 25 (2007) 6677-6691
11. Belgian Health Care Knowledge Centre. HPV vaccination for the prevention of cervical cancer in Belgium. Health Technology Assessment. KCE report Vol. 64C, 2007. Available at: http://www.kce.fgov.be/index_en.aspx?SGREF=9152&CREF=9997 [accessed May 19, 2008].
12. Danish Centre for Health Technology Assessment (DACEHTA). Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV)-a health technology assessment. Health Technology Assessment 2007; 9 (1). Available at: http://www.sst.dk/publ/Publ2007/MTV/HPV/HPV_vaccination_en.pdf [accessed June 25, 2008].
13. Norwegian Knowledge Centre for the Health Services. Cost-effectiveness of human papillomavirus (HPV) vaccination in Norway. Health Technology Assessment Nr 12-2007. Available at: http://www.kunnskapssenteret.no/filer/rapport_0712_HPVdel2.pdf [accessed January 8, 2008].
14. Kulasingam S.L., Benard S., Barnabas R.V., Largeron N., and Myers E.R. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 6 (2008) 4
15. Dasbach E., Elbasha E., and Insinga R. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28 (2006) 88-100
16. Layte R, McGee H, Quail A, Rundle K, Cousins G, Donnelly C, Mulcahy F, Conroy R. The Irish Study of Sexual Health and Relationships (ISSHR). Published by the Crisis Pregnancy Agency and the Department of Health and Children. October 2006. Available at: http://www.crisispregnancy.ie/pub/isshrmainii.pdf [accessed May 15, 2008].
17. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
18. Clifford G., Rana R., Franceschi S., Smith J.S., Gough G., and Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1157-1164
19. Smith J., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 (2007) 621-632
20. Sigurdsson K., Taddeo F., Benediktsdottir K., Olafsdottir K., Sigvaldason H., Oddsson K., et al. HPV genoptypes in CIN 2-3 lesions and cervical cancer: a population-based study. Int J Cancer 121 (2007) 2682-2687
21. Kitchener H., Almonte M., Wheeler P., Desai M., Gilham C., Bailey A., et al. ARTISTIC Trial Study Group. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 95 (2006) 56-61
22. Butler D., Collins C., Mabruk M., Barry Walsh C., Leader M.B., and Kay E.W. Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features. J Pathol 192 (2000) 502-510
23. O'Leary J., Landers R., Crowley M., Healy I., O'Donovan M., Healy V., et al. Human papillomavirus and mixed epithelial tumors of the endometrium. Hum Pathol 29 (1998) 383-389
24. O'Leary J., Landers R., Silva I., Uhlmann V., Crowley M., Healy I., et al. Molecular analysis of ras oncogenes in CIN III and in stage I and II invasive squamous cell carcinoma of the uterine cervix. J Clin Pathol 51 (1998) 576-582
25. Skyldberg B., Murray E., Lambkin H., Kelehan P., and Auer G.U. Adenocarcinoma of the uterine cervix in Ireland and Sweden: human papillomavirus infection and biologic alterations. Mod Pathol 12 (1999) 675-682
26. Keegan H., Ryan F., Malkin A., Griffin M., and Lambkin H. Human papillomavirus prevalence and genotypes in an opportunistically screened Irish female population. Br J Biomed Sci 64 (2007) 18-22
27. Cotton S., Sharp L., Little J., Duncan I., Alexander L., Cruickshank M.E., et al., The TOMBOLA Group. Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): trial design. Cont Clin Trials 27 (2006) 449-471
28. Health Service Executive (HSE). Ready reckoner of acute hospital inpatient activity and costs (summarised by DRG) relating to 2005 costs and activity. Casemix Unit of the National Hospitals Office. Annual Report 2007, Part 3.
29. Rash R, Prenderville W, Byrne P, Stratton J, Redmond S. The cost of treating and managing abnormal cervical conditions in Ireland. Abstract No. PCN39, Presented at ISPOR 10th annual European congress, Dublin, Ireland, October 20-23, 2007.
30. National Immunisation Uptake Statistics (Summary)-Q1 1999-Q4 2007. http://www.ndsc.ie/hpsc/A-Z/VaccinePreventable/Vaccination/ImmunisationUptakeStatistics/ImmunisationUptakeStatisticsSummary/File,954,en.pdf [accessed June 2008].
31. Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health. Advanced on-line access December 26, 2007.
32. Tilson L., Usher C., Butler K., Fitzsimons J., O'Hare F., Cotter S., et al. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland. Val Health 11 September/October (5) (2008)
33. European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in EU countries. Stockholm, January 2008. Available at: http://ecdc.europa.eu/pdf/HPV_report.pdf [Accessed April 2, 2008].
34. Ades A.E., Claxton K., and Sculphur M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Econ 15 4 (2006) 373-381
35. Briggs A.H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17 5 (2000) 479-500